Natural drug leads as novel DPP-IV inhibitors targeting the management of type 2 diabetes mellitus

Wasana, Keddagoda Gamage Piyumi; Attanayake, Anoja Priyadarshani; Jayatilaka, Kamani Ayoma Perera Wijewardana; Weerarathna, Thilak Priyantha

doi:10.5455/jcmr.20190925040807

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The DPP-IV enzyme is reported to inactivate the incretin hormones, and further hampers insulinotropic activity. DPP-IV inhibitors block DPP-IV enzyme activity, extending the half-life of incretins, and this phenomenon has become one of the modest pharmaceutical targets in the treatment of T2DM (Wasana et al, 2020). This is the first attempt in assessing the inhibitory activity of the DPP-IV enzyme in the leaves of C. grandis.…”

Section: Discussionmentioning

confidence: 99%

Chemical composition of the dietary supplement Coccinia grandis (L.) Voigt, and its effect on antioxidant status and inflammatory markers in patients with type 2 diabetes mellitus

Wasana,

Attanayake,

Arawwawala

et al. 2022

IFRJ

View full text Add to dashboard Cite

Herbal dietary supplements are widely used throughout the world with reports of their use among patients with type 2 diabetes mellitus (T2DM). The present work aimed to provide a comprehensive depiction of the dietary supplement Coccinia grandis (L.) Voigt (in the form of aqueous extract of freeze-dried powder), and to determine its antioxidant and anti-inflammatory effects in patients with T2DM. The antioxidant and anti-inflammatory effects of the dietary supplement were evaluated through a three-month long, randomised, double-blind, placebo-controlled clinical trial involving 158 newly diagnosed patients with T2DM. The dietary supplement consisted of phytoconstituents including loliolide, neophytadiene, palmitic acid methyl ester, among others. The absence of microorganisms was observed for a month at 40°C. In vitro antidiabetic assays revealed the inhibition of α-amylase, α-glucosidase, and dipeptidyl peptidase-IV enzymes, and also the enhancement of glucose uptake in cells. Administration of C. grandis dietary supplement (500 mg/day) for three months was able to change variables from the baseline to the end of the intervention, in the test and placebo groups, as -3.25 ± 3.93 and 1.42 ± 4.84 U/L for glutathione reductase (p < 0.001), 12.75 ± 33.35 and -1.45 ± 41.93 nmol/dL for malonaldehyde (p = 0.025), and 5.89 ± 11.49 and 0.46 ± 13.11 pg/mL for interleukin-6 (p = 0.002), respectively. The standardised dietary supplement showed antidiabetic activity in vitro. The clinical study revealed its promising commercial application as a dietary supplement, by improving antioxidant status and reducing inflammation in newly diagnosed patients with T2DM.

show abstract

Section: Discussionmentioning

confidence: 99%

Chemical composition of the dietary supplement Coccinia grandis (L.) Voigt, and its effect on antioxidant status and inflammatory markers in patients with type 2 diabetes mellitus

Wasana,

Attanayake,

Arawwawala

et al. 2022

IFRJ

View full text Add to dashboard Cite

show abstract

“…According to data from the International Diabetes Federation (IDF), 463 million adults (20–79 years) had DM in year 2019, and by 2045, that figure is anticipated to elevate to 700 million. In addition to the macrovascular complications of diabetes such as stroke, peripheral arterial disease, and coronary artery disease, the microvascular complications of diabetes such as diabetic neuropathy, retinopathy and nephropathy, are also exacerbated by hyperglycemia [89–91] . The administration of M. micrantha ethanolic leaf extract for the duration of 30 days remarkably diminished the mean fasting blood glucose level on alloxan‐mediated diabetic rats due to the stimulation of insulin‐producing β‐cells of the pancreas [29]…”

Section: Traditional Usesmentioning

confidence: 99%

Mikania micranthaKunth: An Ethnopharmacological Treasure Trove of Therapeutic Potential

Ali Khan,

El‐Kersh,

Islam

et al. 2023

Chemistry & Biodiversity

View full text Add to dashboard Cite

Mikania micrantha is utilized as a therapeutic for the treatment of various human ailments including insect bites, rashes and itches of skin, chicken pox, healing of sores and wounds, colds and fever, nausea, jaundice, rheumatism, and respiratory ailments. This study aimed at summarizing the traditional uses, phytochemical profile, and biological activities of M. micrantha based on obtainable information screened from different databases. The results suggest that fresh leaves and whole plant are frequently used in folk medicine. The plant contains more than 150 different phytochemicals under the following groups: essential oils, phenolics and flavonoids, terpenes, terpene lactones, glycosides, and sulfated flavonoids. It contains carbohydrates and micronutrients including vitamins and major and trace minerals. M. micrantha possesses antioxidant, anti‐inflammatory, anti‐microbial, anti‐dermatophytic, anti‐protozoal, anthelmintic, cytotoxic, anxiolytic, anti‐diabetic, lipid‐lowering and antidiabetic, spasmolytic, memory‐enhancing, wound‐healing, anti‐aging, and thrombolytic activities. No clinical studies have been reported to date. M. micrantha might be one of the potential sources of phytotherapeutic compounds against diverse ailments in humans. Studies are required to confirm its safety profile in experimental animals prior to initiating clinical trials. Moreover, adequate investigation is also crucial to clarify exact mechanism of action for each biological effect.

show abstract

“…According to studies that have been published, this ingredient berberine extracted from the roots and bark of the B. aristata plant suppressed the enterotoxin secretory response of Vibrio cholera and E. coli in rabbit ligated intestinal loop model and neonatal mouse assay. Moreover, a simple dry formulation of the B. aristata plant prevents cholera toxin-induced diarrhoea [25].…”

Section: Antidiarrhealmentioning

confidence: 99%

Test

2023

Int. J.Exp. Biomed. Res.

View full text Add to dashboard Cite

show abstract

Natural drug leads as novel DPP-IV inhibitors targeting the management of type 2 diabetes mellitus

Cited by 3 publications

References 0 publications

Chemical composition of the dietary supplement Coccinia grandis (L.) Voigt, and its effect on antioxidant status and inflammatory markers in patients with type 2 diabetes mellitus

Chemical composition of the dietary supplement Coccinia grandis (L.) Voigt, and its effect on antioxidant status and inflammatory markers in patients with type 2 diabetes mellitus

Mikania micranthaKunth: An Ethnopharmacological Treasure Trove of Therapeutic Potential

Test

Contact Info

Product

Resources

About